Association of ROR1 with DOCK2 in primary CLL cells. (A) Immunoblot analysis of anti-ROR1 (cirmtuzumab) ip or control IgG (Ctrl-IgG) ip, as indicated at the top, using lysates prepared from freshly isolated primary CLL cells (representative of 3 patients); the membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the CLL is provided in the bottom panel. (B) Immunoblot analysis of anti-DOCK2 ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from freshly isolated primary CLL cells (representative of 3 patients); the membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the CLL is provided in the bottom panel. (C) Immunoblot analysis of anti-ROR1 (cirmtuzumab) ip, using lysates prepared from overnight, serum-starved primary CLL cells (representative of 3 patients) that subsequently were treated for 30 minutes without (−) or with (+) Wnt5a (100 ng/mL), as indicated on the top; the membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the CLL is provided in the bottom panel. (D) Immunoblot analysis of anti-ROR1 (4A5) ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from freshly isolated primary CLL cells (representative of 3 patients) that had been treated with cirmtuzumab (10 μg/mL), without (−) or with (+) Wnt5a (100 ng/mL), as indicated on the top; membranes were probed with anti-ROR1 or anti-DOCK2 antibody, as indicated on the left. An immunoblot of the whole-cell lysates of the CLL treated with cirmtuzumab and probed with anti-DOCK2 mAb is provided in the bottom panel.